Effectiveness of aspirin and aspririnmetformin combination preventing preeclampsia

To compare the effectiveness of aspirin and aspririnmetformin combination preventing preeclampsia in high risk pregnant women with abnormal ultrasonic findings in uterine artery a randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140317017035N9

Enrollment

322

Registered

2024-05-18

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia. Pre-eclampsia

Interventions

Intervention 1: Intervention group: Aspirin 160 mg and metformin 1000 mg. Intervention 2: Control group: Aspirin with a dose of 160 mg and placebo.

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: The singleton pregnant women who are high risk for uteroplacental ischemia and preclampsia based on increased uterine artery resistant on first trimester doppler ultarasonography.

Exclusion criteria

Exclusion criteria: Multiple pregnancy Fetal aneuploidy Fetal anomaly Allergy to aspirin Women who use aspirin or heparin before starting study Coagulation disorder

Design outcomes

Primary

Measure	Time frame
Decrease fetal mortality and morbidity due to preeclampsia. Timepoint: After birth. Method of measurement: Vital Signs.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Shartinia

Shiraz University of Medical Sciences

fshariati85@yahoo.com+98 71 3647 9830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026